α_1肾上腺素能受体阻滞剂萘哌地尔治疗慢性非细菌性前列腺炎的临床研究

目的:探讨α1肾上腺素能受体阻滞剂萘哌地尔(Naftopidil)治疗慢性非细菌性前列腺炎的有效性及安全性。方法:采用开放、自身对照、多中心的临床试验方法,应用萘哌地尔25mg,每日1次,对106例慢性非细菌性前列腺炎(NBP)患者进行了为期4周的治疗。以美国国立卫生院慢性前列腺炎症状评分(NIHCPSI)、前列腺液(EPS)WBC计数及最大尿流率(MFR)为疗效指标,对其有效性及安全性进行观察。结果:服药4周后,可评价病例105例。全组患者NIHCPSI总评分治疗前后平均减低12.0分(P<0.001),症状评分平均减低7.9分(P<0.001),生活质量评分平均减低4.1分(P<0.001)。EPS中WBC计数治疗前及治疗后分别为(15.2±15.1)、(9.5±12.0)个/HP(P<0.01)。MFR治疗前及治疗后分别为(19.2±4.8)、(22.7±4.9)ml/s(P<0.01)。按症状改善评价,治愈2例(1.9%),显效32例(30.5%),有效55例(52.4%),无效16例(15.2%)。总显效率为32.4%,总有效率为84.8%。3例有轻度头晕,1例食欲不佳,不良事件发生率3.81%。结论:萘哌地尔治疗慢性非细菌性前列腺炎安全、有效。     

舍尼通~和抗生素联合用药治疗慢性非细菌性前列腺炎临床研究

目的:评价舍尼通与抗生素联合用药治疗慢性非细菌性前列腺炎的有效性及耐受性。方法:采用双盲、平行对照、多中心临床试验研究方法,通过Stam ey试验、前列腺按摩液(EPS)常规及美国国立卫生院慢性前列腺炎症状评分(NIH-CPSI),筛选出160例慢性非细菌性前列腺炎患者,随机分为试验组(80例,脱落1例)和对照组(80例)。试验组前4周合用舍尼通和左氧氟沙星,后4周单用舍尼通,服用剂量为舍尼通2次/d,1片/次,左氧氟沙星2次/d,0.1 g/次;对照组方法同上,仅将舍尼通换为安慰剂。所有患者均行入组前、治疗第4周和第8周随访并行NIH-CPSI评分、EPS等检查及药物不良反应的评估。结果:治疗后4周和8周,试验组疼痛评分降低分别为3.34±2.45,4.33±3.13,排尿评分降低分别为2.22±1.79,2.77±2.04;对照组疼痛评分降低分别为2.28±2.42,3.30±3.29,排尿评分降低分别为1.24±1.67,1.83±2.25。两组治疗前后的自身对比均差异有显著性(P<0.01),生活质量影响评分差异也有显著性(P<0.05)。组间比较,试验组较对照组第4周和第8周疼痛和排尿评分差异均有显著性(P<0.01或P<0.05)。两组治疗前后白细胞、卵磷脂小体差异无显著性(P>0.05),对药物的耐受性差异无显著性(P>0.05),无严重不良反应事件发生。结论:舍尼通与抗生素联合用药方案能更有效地缓解慢性非细菌性前列腺炎患者的疼痛不适症状和排尿症状,耐受性好,值得在临床上推广应用。     

慢性移植肾失功后的移植肾切除手术分析

目的:分析总结因慢性移植肾失功而行移植肾切除手术患者的临床治疗经过,进一步探讨这类手术的安全性和适应证。方法:以慢性移植肾失功患者76例为研究对象,年龄23~72(36.6±13.5)岁,以上患者发生慢性移植肾失功的时间为术后11~91(35.8±24.6)个月,转入血液透析的时间为3~33(10.4±6.2)个月。76例患者均实施了移植肾切除手术,移植肾切除术后随访时间为6个月~5年。结果:平均手术时间50(35~180)min;术中平均出血量450(200~2 600)ml,平均输血量300(400~2 400)ml,其中67例进行了自体血液回收后输血。术后平均引流量250(20~1 100)ml,平均住院时间11(5~23)d。术后主要并发症:切口血肿8例,切口感染10例,消化道出血7例,心衰7例,肺部感染5例,肾上腺危象2例,下肢跛行2例。死亡4例。多数患者的体重指数、血红蛋白及血清白蛋白含量较术前有所提高。结论:慢性移植肾失功后的移植肾切除手术为高风险手术,应积极做好术前准备,同时加强围手术期护理,以降低手术并发症的发生率;积极适时地切除已经完全失功了的移植肾,有助于改善患者身体素质,避免免疫抑制的不良反应,同时有利于减轻患者本人及社会的经济负担。     

盐酸特拉唑嗪治疗中国人群良性前列腺增生患者的多中心临床研究

目的 评价维持剂量盐酸特拉唑嗪治疗中国人群BPH患者的有效性、安全性和依从性. 方法2007年6月至2008年3月在中国32家泌尿外科中心开展了多中心、前瞻性临床研究,方案为口服盐酸特拉唑嗪1～4 mg,1次/d,共4周.主要评价指标是治疗2、4周时患者IPSS变化值;次要指标是治疗4周时Qmax,QOL变化值,治疗2、4周时血压变化值以及4周内脱落率.并通过对不良事件的分析评估其安全性. 结果共纳入1006例BPH患者(FAS集),资料合格者992例(PP集),合并高血压病344例.FAS集患者IPSS从基线的22.32±6.13降至2周时的16.98±5.92以及4周时的14.00±5.52(P＜0.01);PP集患者IPSS从基线的22.32±6.15降至2周时的16.96±5.93及4周时的13.95±5.52(P＜0.01).以IPSS与基线相比下降＞30%定义为有效,2周末有效率为26.54%,4周末为60.64%.治疗4周后Qmax 和QOL均有显著增高,分别改善32%和45%(P＜0.01).对于血压正常或高血压获得控制的患者,盐酸特拉唑嗪对血压的影响较小;而对伴有未治疗或未能控制血压的高血压患者,盐酸特拉唑嗪能一定程度降低血压(P＜0.05).治疗中不良事件发生率低,最常见为头晕(3.68%).研究结束时960例仍继续服药. 结论盐酸特拉唑嗪能有效改善中国人群BPH患者症状,显著提高生活质量,同时具有良好的安全性和依从性.     

简体中文版King健康问卷在膀胱过度活动症患者中应用的信度和效度分析

目的 评价简体中文版King健康问卷(KHQ)在膀胱过度活动症(OAB)患者中应用的信度和效度.方法 采用"WHO-QOL跨文化生活质量研究问卷翻译法"将英文版KHQ翻译成简体中文,随机抽取就诊于泌尿外科门诊的OAB患者,在第0周和第2周对其进行2次简体中文版KHQ问卷调查.通过Cronbach's α系数评价问卷的内部一致性;用组内相关系数(ICC)评价重测信度;计算各问题得分与所属领域得分的Spearman等级相关系数(rs)评价内容效度;用因子分析评价结构效度.结果 48例符合纳入标准的OAB患者参与本研究,40例完成2次调查,男7例,女33例,年龄(49.6±14.3)岁.KHQ各亚量表和各领域均具有较好的内部一致性(Cronbach's α:0.7l8～0.924)、中到高的重测信度(ICC:0.567～0.995,P<0.01)以及中到高的内容效度(r:0.462～0.964,P<0.01).因子分析法显示简体中文版KHQ具有可接受的结构效度.结论简体中文版KHQ具有较好的信度和效度,可作为评估OAB患者生活质量的专用量表.     

基于1H-NMR代谢组学的阿胶化学成分差异性分析方法初探

目的 采用氢核磁共振(¹H-NMR)代谢组学技术对不同生产厂家的阿胶酸水解成分进行差异性比较。方法 对5个不同生产厂家的阿胶进行酸水解,然后进行¹H-NMR分析。对所得的¹H-NMR图谱进行化学成分归属指认,并结合相关软件进行多元统计分析,找出差异性化学成分。结果 从阿胶¹H-NMR谱中指认出17种化学成分;通过对A、C、D、E厂家生产的阿胶与B厂家生产的阿胶进行比较分析,找出了相应的差异性成分,主要包括异亮氨酸、羟脯氨酸、精氨酸、亮氨酸、苯丙氨酸、缬氨酸、赖氨酸和乙酰丙酸等。结论 ¹H-NMR代谢组学方法可用于不同厂家阿胶化学成分差异性的分析,为阿胶的质量控制提供新方法和新思路。     

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease

Infusions of large numbers (> 10(8)/kg) of donor leukocytes can induce remissions in patients with chronic myeloid leukemia (CML) who relapse after marrow transplantation. We wanted to determine if substantially lower numbers of donor leukocytes could induce remissions and, if so, whether this would reduce the 90% incidence of graft-versus-host disease (GVHD) associated with this therapy. Twenty-two patients with relapsed CML were studied: 2 in molecular relapse, 6 in cytogenetic relapse, 10 in chronic phase, and 4 in accelerated phase. Each patient received escalating doses of donor leukocytes at 4- to 33-week intervals. Leukocyte doses were calculated as T cells per kilogram of recipient weight. There were 8 dose levels between 1 x 10(5) and 5 x 10(8). Lineage-specific chimerism and residual leukemia detection were assessed using sensitive polymerase chain reaction (PCR) methodologies. Nineteen of the 22 patients achieved remission. Remissions were achieved at the following T-cell doses: 1 x 10(7) (n = 8), 5 x 10(7) (n = 4), 1 x 10(8) (n = 3), and 5 x 10(8) (n = 4). To date, 15 of the 17 evaluable patients have become BCR-ABL negative by PCR. The incidence of GVHD was correlated with the dose of T cells administered. Only 1 of the 8 patients who achieved remission at a T-cell dose of 1 x 10(7)/kg developed GVHD, whereas this complication developed in 8 of the 11 responders who received a T-cell dose of > or = 5 x 10(7)/kg. Three patients died in remission, 1 secondary to marrow aplasia, 1 of respiratory failure and 1 of complications of chronic GVHD. Sixteen patients who were mixed T-cell chimeras before treatment became full donor T-cell chimeras at the time of remission. Donor leukocytes with a T-cell content as low as 1 x 10(7)/kg can result in complete donor chimerism together with a potent graft-versus-leukemia (GVL) effect. The dose of donor leukocytes or T cells used may be important in determining both the GVL response and the incidence of GVHD. In many patients, this potent GVL effect can occur in the absence of clinical GVHD.     

Protein Losing Enteropathy in Severe Atopic Dermatitis in an Exclusively Breast-Fed Infant

Abstract:   We first report a case of protein losing enteropathy in severe atopic dermatitis in an exclusively breast-fed 5-month-old infant. Protein losing enteropathy was confirmed by fecal α₁-antitrypsin clearance test and imaged successfully by ^99mTc-human serum albumin scintigraphy. The present case highlights that protein losing enteropathy in severe infantile atopic dermatitis is being a topic of concern and also an issue even in exclusive breast feeding patients.     

Flexion compromises ventilation with the laryngeal tube suction II in children

Background: There are insufficient data as to the influence of the head and neck flexion, extension, and rotation on the ventilation with laryngeal tube suction II^® (LTS II). The purpose of this study was to investigate the influence of the head and neck position on oropharyngeal sealing pressure (primary outcome) and ventilation score (secondary outcome) during ventilation with the LTS II in children. Methods: We studied 33 children scheduled for elective surgery. Oropharyngeal sealing pressure and ventilation score were measured with the head and neck in a neutral position, flexed, extended and rotated to the right. The ventilation score was scored from 0 to 3 based on three items (no leakage with an airway pressure of 15 cmH₂O, bilateral chest excursion, and a square wave capnogram; each item scored 0 or 1 point). Peak inspiratory pressure (PIP) at a tidal volume of 10 ml·kg^?1 and fiberoptic laryngeal views were also assessed in each position. Results: Although the sealing pressure was lower in the extended position [22 (8) cmH₂O] than that in the neutral position [25 (7) cmH₂O], there was no significant leakage during ventilation with a tidal volume of 10 ml·kg^?1. In the neutral, extended and rotated positions, the median ventilation scores were better (3 point respectively) than that with the head and neck flexed (1 point). PIP was decreased with the head and neck extended or rotated but was significantly increased in flexion position. During fibreoptic examination, the vocal cords were more easily seen in extension and right rotation, compared with the neutral position and flexion. Conclusions: Although oropharyngeal sealing pressure is decreased with the head and neck extended, effective ventilation with LTS II can be performed like in the neutral position or the rotated position. While the sealing pressure is maintained with the head and neck flexed, flexion compromises the ventilation with LTS II in children.     

针刺治疗慢性无菌性前列腺炎文献系统评价

目的：系统评价针刺治疗慢性无菌性前列腺炎（CNBP）的有效性。方法：按照循证医学的要求,以针刺、体针、电针、头针、CNBP等为主题词,检索国内相关医学数据库,以随机临床对照试验为纳入标准。治疗组为针刺或针刺加其他疗法,对照组为药物,把CNBP痊愈率为测量指标。共纳入33篇文献,并对其中6篇文献采用RevMan4．2．9进行Meta分析。结果：6篇文献的痊愈率合并OR=3．48,95％CI[2．46,4．92],治疗组对CNBP的疗效优于对照组（P〈0．05）。结论：从纳入的国内文献来看,针刺治疗CNBP有效,且效果优于药物,但是仍需要更多的高质量文章来证实。